ABBV AbbVie Inc. — dividend yield, history & ex-dividend dates
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Dividend Snapshot
Research Scores
Scores describe this security's published financial data on a 0–100 scale using the formulas on our methodology pages. They are the same for every reader, are not a probability or a forecast, and are not a recommendation. Past dividend growth does not guarantee future increases. Report a data error.
How the Dividend Safety Score is built for ABBV
| Input | Value | Points | Weight |
|---|---|---|---|
| Earnings payout ratio | Earnings payout ratio 190% (TTM to Jun 30, 2026) | 0 | 20% |
| FCF payout ratio | FCF payout ratio 66% (TTM to Jun 30, 2026) | 80 | 25% |
| Net debt / EBITDA | Net debt / EBITDA 3.0x (TTM to Jun 30, 2026) | 59 | 15% |
| Interest coverage | Interest coverage 4.6x (TTM to Jun 30, 2026) | 64 | 10% |
| Dividend record | 13 years of uninterrupted regular payments | 74 | 20% |
| Earnings stability | Net income positive in 5 of the last 5 fiscal years (FY2021–FY2025) | 100 | 10% |
Inputs that are not available are left out and the remaining weights are scaled up. Profile: ordinary company. Formula version 2026-10-19.4.
How the Dividend Growth Score is built for ABBV
| Input | Value | Points | Weight |
|---|---|---|---|
| 5-year dividend growth | 5-year dividend CAGR 6.8% (2020–2025) | 84 | 25% |
| Consecutive annual increases | 12 consecutive annual increases (through 2025) | 83 | 20% |
| Payout headroom | Headroom from the earnings payout ratio 190% (TTM to Jun 30, 2026) | 0 | 20% |
| Earnings per share growth (3 years) | EPS CAGR -29.0% (FY2022–FY2025) | 0 | 15% |
| Revenue growth (3 years) | Revenue CAGR 1.8% (FY2022–FY2025) | 55 | 10% |
| 10-year dividend growth | 10-year dividend CAGR 12.5% (2015–2025) | 100 | 10% |
Inputs that are not available are left out and the remaining weights are scaled up. Profile: ordinary company. Formula version 2026-10-19.4.
How the Dividend Value Score is built for ABBV
| Input | Value | Points | Weight |
|---|---|---|---|
| Yield vs own history | Current yield at the 2nd percentile of its 120 month-end yields | 2 | 40% |
| P/E vs own 5-year median | P/E 80.5 is 1.41x its 5-year median of 57.0 | 7 | 25% |
| FCF yield | FCF yield 3.6% (TTM to Jun 30, 2026) | 49 | 20% |
| P/E vs peers | P/E 80.5 vs peer median 26.8 (3.00x; 45 corporation / Healthcare securities) | 0 | 15% |
Inputs that are not available are left out and the remaining weights are scaled up. Profile: ordinary company. Formula version 2026-10-19.4.
Key Metrics
Current Yield
2.42%
At the Oct 29, 2026 price
The annual dividend as a percentage of the share price. A 3% yield is about $3 of dividends a year for every $100 invested at today's price.Annualized Dividend
$6.9200
Declared Sep 10, 2026
The latest declared regular dividend scaled to a full year by how often it's paid (for semi-annual payers, the latest two payments), adjusted for stock splits. A $0.25 quarterly dividend annualizes to $1.00. Special dividends are excluded.Frequency
Q Quarterly
How often the dividend is paid, read from the dates of recent payments: Q = quarterly (4x a year), M = monthly, S = semi-annual, A = annual.RSI (14)
65
As of Oct 29, 2026
Relative Strength Index (0-100), a price-momentum gauge. Above 70 is often called 'overbought', below 30 'oversold'. A technical signal, not a dividend metric.52-Week Range
$197.38 – $289.08
Closes through Oct 23, 2026
The lowest and highest price over the past year, showing where today's price sits in its recent range.Payout Ratio (TTM)
189.71%
12 months to Jun 30, 2026 (Q2 FY2026)
The share of earnings paid out as dividends over the trailing twelve months (TTM): dividends paid divided by net income across the company's four most recent reported quarters, dated by the latest quarter end. A fiscal-year tag such as FY2025 means only annual figures were available. Lower leaves more cushion; above 100% means paying out more than the company earned. It shows n/a for funds and when net income over the period was negative; for REITs and BDCs it is marked EPS-based, since they are judged on FFO/AFFO or net investment income instead.Years Paying
13
How many years of payments we have on record. This can understate very long histories where our data doesn't reach far enough back.Price / Book (TTM)
-85.23
Price as of Oct 25, 2026; latest reported book value
Price-to-book ratio: the share price on the date shown divided by the latest reported book value per share. A rough valuation gauge, most useful for asset-heavy sectors like REITs, banks and insurers.S.A.F.E. Dividend Read
Quote & Key Data
Dividend Growth
How often a record like this ends in a cut
ABBV has raised its annual dividend in 12 separate years since January 2013, which ranks 932 among the 2,430 payers with a comparable record in our dataset. No year in that span saw the annual total fall by more than a fifth.
Of the 878 companies we track with 10 to 24 years of increases, 661 — 75 per cent — also have at least one year in which the dividend fell by more than 20 per cent. Across every company with twenty years of comparable history, only 277 of 1078 (26 per cent) have never cut. A long record of increases is common; a record with no cut anywhere in it is not.
Measured from annual totals using split-adjusted amounts, comparing only consecutive years with the same number of payments — a stock split and a payment shifting across a year boundary both look like cuts otherwise. The current year is excluded as incomplete. How we measure a cut, and what the corrections change. Figures are for information only, not a view on any security.
Why the Yield Moved (90 Days)
ABBV's dividend yield fell from 2.76% to 2.42% over the past ~90 days (-0.34 pp). Of that move, +0.00 pp came from changes in the dividend rate and -0.34 pp from the share price ($250.94 on Jul 31, 2026 → $286.35 on Oct 29, 2026). A yield that rises because the price fell is not an improvement in the payout itself.
Yield vs Its Own History
Across 273 daily observations over the past 13 months (through Oct 23, 2026), ABBV's current yield is higher than approximately 0% of them. Our stored price history for ABBV covers the past 13 months; 3- and 5-year averages are not yet computable from it and are deliberately not shown.
Adjusted Price History
Dividend History
Dividend Payment History
Ex-dividend calendar →| Amount | Type | Declared | Ex-Date | Record | Pay |
|---|---|---|---|---|---|
| $1.7300 Q | Regular | Sep 10, 2026 | Oct 15, 2026 | Oct 15, 2026 | Nov 16, 2026 |
| $1.7300 Q | Regular | Jun 18, 2026 | Jul 15, 2026 | Jul 15, 2026 | Aug 14, 2026 |
| $1.7300 Q | Regular | Feb 19, 2026 | Apr 15, 2026 | Apr 15, 2026 | May 15, 2026 |
| $1.7300 Q | Regular | Oct 31, 2025 | Jan 16, 2026 | Jan 16, 2026 | Feb 17, 2026 |
| $1.6400 Q | Regular | Sep 05, 2025 | Oct 15, 2025 | Oct 15, 2025 | Nov 14, 2025 |
| $1.6400 Q | Regular | Jun 20, 2025 | Jul 15, 2025 | Jul 15, 2025 | Aug 15, 2025 |
| $1.6400 Q | Regular | Feb 13, 2025 | Apr 15, 2025 | Apr 15, 2025 | May 15, 2025 |
| $1.6400 Q | Regular | Oct 30, 2024 | Jan 15, 2025 | Jan 15, 2025 | Feb 14, 2025 |
| $1.5500 Q | Regular | Sep 06, 2024 | Oct 15, 2024 | Oct 15, 2024 | Nov 15, 2024 |
| $1.5500 Q | Regular | Jun 20, 2024 | Jul 15, 2024 | Jul 15, 2024 | Aug 15, 2024 |
| $1.5500 Q | Regular | Feb 15, 2024 | Apr 12, 2024 | Apr 15, 2024 | May 15, 2024 |
| $1.5500 Q | Regular | Oct 27, 2023 | Jan 12, 2024 | Jan 16, 2024 | Feb 15, 2024 |
| $1.4800 Q | Regular | Sep 08, 2023 | Oct 12, 2023 | Oct 13, 2023 | Nov 15, 2023 |
| $1.4800 Q | Regular | Jun 22, 2023 | Jul 13, 2023 | Jul 14, 2023 | Aug 15, 2023 |
| $1.4800 Q | Regular | Feb 16, 2023 | Apr 13, 2023 | Apr 14, 2023 | May 15, 2023 |
| $1.4800 Q | Regular | Oct 28, 2022 | Jan 12, 2023 | Jan 13, 2023 | Feb 15, 2023 |
| $1.4100 Q | Regular | Sep 09, 2022 | Oct 13, 2022 | Oct 14, 2022 | Nov 15, 2022 |
| $1.4100 Q | Regular | Jun 23, 2022 | Jul 14, 2022 | Jul 15, 2022 | Aug 15, 2022 |
| $1.4100 Q | Regular | Feb 17, 2022 | Apr 13, 2022 | Apr 15, 2022 | May 16, 2022 |
| $1.4100 Q | Regular | Oct 29, 2021 | Jan 13, 2022 | Jan 14, 2022 | Feb 15, 2022 |
| $1.3000 Q | Regular | Sep 10, 2021 | Oct 14, 2021 | Oct 15, 2021 | Nov 15, 2021 |
| $1.3000 Q | Regular | Jun 17, 2021 | Jul 14, 2021 | Jul 15, 2021 | Aug 16, 2021 |
| $1.3000 Q | Regular | Feb 18, 2021 | Apr 14, 2021 | Apr 15, 2021 | May 14, 2021 |
| $1.3000 Q | Regular | Oct 30, 2020 | Jan 14, 2021 | Jan 15, 2021 | Feb 16, 2021 |
| $1.1800 Q | Regular | Sep 11, 2020 | Oct 14, 2020 | Oct 15, 2020 | Nov 16, 2020 |
| $1.1800 Q | Regular | Jun 17, 2020 | Jul 14, 2020 | Jul 15, 2020 | Aug 14, 2020 |
| $1.1800 Q | Regular | Feb 20, 2020 | Apr 14, 2020 | Apr 15, 2020 | May 15, 2020 |
| $1.1800 Q | Regular | Nov 01, 2019 | Jan 14, 2020 | Jan 15, 2020 | Feb 14, 2020 |
| $1.0700 Q | Regular | Sep 06, 2019 | Oct 11, 2019 | Oct 15, 2019 | Nov 15, 2019 |
| $1.0700 Q | Regular | Jun 20, 2019 | Jul 12, 2019 | Jul 15, 2019 | Aug 15, 2019 |
| $1.0700 Q | Regular | Feb 21, 2019 | Apr 12, 2019 | Apr 15, 2019 | May 15, 2019 |
| $1.0700 Q | Regular | Nov 02, 2018 | Jan 14, 2019 | Jan 15, 2019 | Feb 15, 2019 |
| $0.9600 Q | Regular | Sep 07, 2018 | Oct 12, 2018 | Oct 15, 2018 | Nov 15, 2018 |
| $0.9600 Q | Regular | Jun 14, 2018 | Jul 12, 2018 | Jul 13, 2018 | Aug 15, 2018 |
| $0.9600 Q | Regular | Feb 15, 2018 | Apr 12, 2018 | Apr 13, 2018 | May 15, 2018 |
| $0.7100 Q | Regular | Oct 26, 2017 | Jan 11, 2018 | Jan 12, 2018 | Feb 15, 2018 |
| $0.6400 Q | Regular | Sep 08, 2017 | Oct 12, 2017 | Oct 13, 2017 | Nov 15, 2017 |
| $0.6400 Q | Regular | Jun 23, 2017 | Jul 12, 2017 | Jul 11, 2017 | Aug 15, 2017 |
| $0.6400 Q | Regular | Feb 17, 2017 | Apr 11, 2017 | Apr 13, 2017 | May 15, 2017 |
| $0.6400 Q | Regular | Oct 31, 2016 | Jan 11, 2017 | Jan 13, 2017 | Feb 15, 2017 |
| $0.5700 Q | Regular | Sep 09, 2016 | Oct 12, 2016 | Oct 14, 2016 | Nov 15, 2016 |
| $0.5700 Q | Regular | Jun 16, 2016 | Jul 13, 2016 | Jul 15, 2016 | Aug 15, 2016 |
| $0.5700 Q | Regular | Feb 18, 2016 | Apr 13, 2016 | Apr 15, 2016 | May 16, 2016 |
| $0.5700 Q | Regular | Oct 30, 2015 | Jan 13, 2016 | Jan 15, 2016 | Feb 16, 2016 |
| $0.5100 Q | Regular | Sep 11, 2015 | Oct 13, 2015 | Oct 15, 2015 | Nov 16, 2015 |
| $0.5100 Q | Regular | Jun 19, 2015 | Jul 13, 2015 | Jul 15, 2015 | Aug 14, 2015 |
| $0.5100 Q | Regular | Feb 19, 2015 | Apr 13, 2015 | Apr 15, 2015 | May 15, 2015 |
| $0.4900 Q | Regular | Oct 21, 2014 | Jan 13, 2015 | Jan 15, 2015 | Feb 13, 2015 |
| $0.4200 Q | Regular | Sep 19, 2014 | Oct 10, 2014 | Oct 15, 2014 | Nov 17, 2014 |
| $0.4200 Q | Regular | Jun 19, 2014 | Jul 11, 2014 | Jul 15, 2014 | Aug 15, 2014 |
| $0.4200 Q | Regular | Feb 20, 2014 | Apr 11, 2014 | Apr 15, 2014 | May 15, 2014 |
| $0.4000 Q | Regular | Dec 12, 2013 | Jan 13, 2014 | Jan 15, 2014 | Feb 14, 2014 |
| $0.4000 Q | Regular | Sep 19, 2013 | Oct 10, 2013 | Oct 15, 2013 | Nov 15, 2013 |
| $0.4000 Q | Regular | Jun 20, 2013 | Jul 11, 2013 | Jul 15, 2013 | Aug 15, 2013 |
| $0.4000 Q | Regular | Feb 15, 2013 | Apr 11, 2013 | Apr 15, 2013 | May 15, 2013 |
| $0.4000 Q | Regular | Jan 07, 2013 | Jan 11, 2013 | Jan 15, 2013 | Feb 15, 2013 |
Peer Comparison
Selected Drug Manufacturers - General dividend payers we cover, strongest DividendRank first — for context, not a recommendation.
| Ticker | Name | Yield | 5-Yr Growth | Streak | Rank |
|---|---|---|---|---|---|
| ZTS | Zoetis Inc. | 2.72% | 20.1% | 11 yrs | 95 |
| BMY | Bristol-Myers Squibb Company | 4.16% | 6.6% | 18 yrs | 86 |
| ALPMY | Astellas Pharma Inc. | 3.12% | 5.6% | 11 yrs | 80 |
| ALPMF | Astellas Pharma Inc. | 2.87% | 5.9% | 3 yrs | 80 |
Related Guides & Lists
ABBV dividend — frequently asked questions
Does AbbVie Inc. pay a dividend?
Yes. AbbVie Inc. (ABBV) currently pays a dividend. The annualized dividend is about $6.92 per share, a yield of approximately 2.42%.
What is AbbVie Inc.'s dividend yield?
AbbVie Inc.'s dividend yield is approximately 2.42%, based on the most recent regular payment annualized against the current share price. Yields move as the share price changes.
How often does AbbVie Inc. pay dividends?
AbbVie Inc. pays dividends quarterly — 4 times per year.
How long has AbbVie Inc. paid dividends?
AbbVie Inc. has 13 years of dividend payments on record, and has increased its dividend for 12 consecutive years.
Data updated Oct 29, 2026. This research page is generated from Dividendly's structured market and dividend dataset using the approach described on our methodology and data sources pages. Data is automatically validated using defined rules and may also be periodically reviewed. Research only, not investment advice. Spotted a data error? Report it.